When was Salus Therapeutics founded?
Salus Therapeutics was founded in 1999.
Where is Salus Therapeutics's headquarters?
Salus Therapeutics's headquarters is located at Salt Lake City.
What is Salus Therapeutics's latest funding round?
Salus Therapeutics's latest funding round is Acquired.
How much did Salus Therapeutics raise?
Salus Therapeutics raised a total of $4.25M.
Who are the investors of Salus Therapeutics?
Investors of Salus Therapeutics include Genta, WS Investments, vSpring Capital and Pelion Venture Partners.
Who are Salus Therapeutics's competitors?
Competitors of Salus Therapeutics include Cevec Pharmaceuticals, Acura Pharmaceuticals, Esperance Pharmaceuticals, Angstrom Pharmaceuticals, Oxyrane and 12 more.
You May Also Like
Oxyrane is a biopharmaceutical company dedicated to the development of biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases.
The company are a technology development and licensing firm with a strong focus on robotics and machine intelligence applications and their integration into industries such as pharmaceuticals and health care. The company take great pride in the company's diverse and knowledgeable staff, who make such ventures possible. Wrightwood Technologies Inc. aims to provide both the public and private sectors with technologies and services that improve efficiency, increase production, reduce costs, eliminate waste, and improve societies' over-all quality of life.
Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..
Neuromark is aiming to develop genetic answers for the new era in neuropsychiatry.
Message Pharmaceuticals, Inc. is leveraging its platform technology in developing new classes of drugs that mimic RNA binding proteins to treat all major disease categories.
Frio Pharmaceuticals is dedicated to oral-systemic health and was spun out of Biomedical Development Corporation (BDC), its research affiliate, in 1999 to manufacture and sell a dental waterline cleaner. This platform technology has evolved into a pipeline of pharmaceuticals to treat oral diseases and interrupt the disease process. Its goal is to commercialize a broad-spectrum antimicrobial platform technology with products being: (1) a pharmaceutical to treat thrush (oral candidiasis) in cancer patients with thrush and (2) a pharmaceutical to treat gingivitis (oral inflammation).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.